Drug Approval | January 03, 2024
Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24
The company has received five final approvals
The company has received five final approvals
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
Furthering cell therapy ambition across oncology and autoimmune diseases
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Ami Organics will also sign an MoU with Government of Gujarat for investment amounting up to Rs 300 crores for set up of dedicated manufacturing facility for electrolytes business
Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201
His most recent stint was with Danone India as its Managing Director
Subscribe To Our Newsletter & Stay Updated
